MK 912Alternative Names: L 657743; MK-912
Latest Information Update: 18 Feb 2008
At a glance
- Originator Merck & Co
- Class Antidepressants
- Mechanism of Action Alpha 2 adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 14 Dec 1999 Phase-II clinical trials for Depression in USA (PO)
- 23 Jun 1997 No-Development-Reported for Depression in USA (PO)